QDEL
QuidelOrtho Corporation

QuidelOrtho CorporationQDEL

Healthcare · Medical Devices
14.35USD
+1.85%
Nov 05, 2026
QDEL overview ready
Diagnostic testing instruments and assays for healthcare providers
QuidelOrtho is a diversified in-vitro-diagnostics supplier with laboratory, immunohematology/transfusion, point-of-care, and molecular-testing franchises.
Theme not measured
No economic group is assigned yet.
Price trend is broken
Longer-term context reads early recovery, with a near-term setup of reclaim attempt.
Demanding valuation
The price embeds expectations that run ahead of the strength of its balance sheet.
Solid fundamentals
Free cash flow yield is strong.
Primary risk
Dependence on healthcare provider purchasing cycles.
Market Nov 4Price action Nov 5Research Oct 13

Conviction Level

Theme Momentum has no canonical measurement for this company — a research-profile dimension, not an input to this score.

PriceAction8.6BusinessPerformance2.0BusinessQuality3.2Valuation3.2ThemeMomentum—Weakening — Revenue fell 12% year over year in the latest quarter. The company is still loss-making: the diluted loss per share narrowed to -$0.78 from -$10.78 a year earlier. — From filed financial statements. Describes the recent trajectory of the business, not the stock. 20 of the 100 Conviction points.

Conviction uses Price Action, Business Performance, Business Quality, Valuation. Theme Momentum is research context, not an input.

Theme momentumPrimary theme · group context, not entry timing
No economic group yet — pending research
Price
Loading price history…

Price Action

Price trend is broken
Longer-term context reads early recovery, with a near-term setup of reclaim attempt.
EntryReset + recovery

The stock is still rebuilding below its long-term weekly base, and the recent reset toward the daily SMA200 aligned with support at the weekly EMA21. Daily structure is recovering above the fast averages, improving the current entry location.

Key Financials

Market Cap
$905.0M
Avg Volume (60D)
2.0M
60 sessions
Revenue Growth YoY
-2.6%
Trailing twelve months
Gross Margin
+44.9%
Operating Margin
-1.2%
Trailing twelve months
Free Cash Flow Yield
+16.2%
EV / EBITDA
8.0x
EV / Sales
1.4x
Market metrics as of Nov 4, 2026

Business Performance

Weakening

Revenue fell 12% year over year in the latest quarter. The company is still loss-making: the diluted loss per share narrowed to -$0.78 from -$10.78 a year earlier.

Latest reported: Q3 FY2026, ended Sep 27
Revenue growthDeclining
-12%
$619M in Q3 FY2026 · YoY
YoY growth, last 4 quarters
  1. n/a
  2. -11%
  3. +2.8%
  4. -12%
Earnings growthLoss narrowing
-$0.78
Diluted EPS -$0.78 vs -$10.78 a year earlier · GAAP
Too few comparable EPS quarters: a loss or a turn to profit has no meaningful percentage.
Operating marginExpanding
-1.2%
+99.5 pp YoY

Business Quality

3.2 / 10

How well the business earns on its assets, converts earnings to cash and funds itself — read from its SEC filings.

Fundamentals & Valuation

The available comparisons disagreed; the intrinsic comparison is the more reliable method for this business and the others are published as dissent.
This company has an Expensive valuation stance because the price embeds expectations that run ahead of the strength of its balance sheet. It trades at 1.4x revenue, which requires sustained delivery to be justified.

Company Research

Thesis
QuidelOrtho is a diversified in-vitro-diagnostics supplier with laboratory, immunohematology/transfusion, point-of-care, and molecular-testing franchises.
Opportunity
Limited opportunity
Healthcare-provider adoption of rapid molecular testing platforms that move clinically actionable diagnostic results closer to the patient, emergency department, clinic, or other near-patient settings rather than relying solely on centralized laboratories.
Key risk
Dependence on healthcare provider purchasing cycles.

Economic classification

Loading the economic classification…

Business & Markets

Healthcare · Medical Devices
What they do

QuidelOrtho Corporation develops and sells diagnostic testing solutions through multiple business units including Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics, providing instruments and tests for clinical and patient health evaluation.

How it earns

The company generates revenue primarily through transactional sales of diagnostic instruments, tests, and related consumables to healthcare providers and laboratories.

Products & services
Clinical chemistry laboratory instruments and tests
Immunoassay laboratory instruments and tests
Point of care diagnostic tests
Molecular diagnostic tests
Customers & end markets
Hospitals and clinical laboratories
Transfusion medicine centers
Point of care healthcare providers
Market position

QuidelOrtho is a recognized player in the diagnostic testing market with a diversified product portfolio across multiple diagnostic segments.

Demand drivers
Low cyclicality

Healthcare diagnostic testing demand tends to be stable and less sensitive to economic cycles.